Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
bot .starter yesterday
red to green, phase 2 top line results going into phase 3 in june. investment not a day trade
starter
HOOK nice one
cash on hand to fund operations till 2024 catalyst in june , in for starter
held gains
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Dermata raised $5 million gross proceeds from a public offering in March 2023 -
- Dermata submitted an End of Phase 2 meeting package to FDA in April 2023 -
- FDA agreed that Dermata's chemistry, manufacturing, and control ("CMC") procedures support the initiation of Phase 3 studies of DMT310 for the treatment of acne -
SAN DIEGO, CA / ACCESSWIRE / May 11, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress, and reported financial results for the first quarter ended March 31, 2023.
"We are very encouraged by FDA's agreement that our current CMC procedures for DMT310 are adequate to support progressing DMT310 into our Phase 3 program in moderate-to-severe acne. This was a big hurdle for Dermata as DMT310 is a novel product candidate and potentially could be the first naturally-derived prescription product for the treatment of acne," said Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "We are also excited to have submitted our DMT310 End of Phase 2 meeting package to FDA, which will allow Dermata an opportunity to engage FDA in a discussion regarding our proposed Phase 3 clinical program for acne. We believe we have met all the requirements to move forward with our Phase 3 acne program and look forward to receiving FDA feedback by the end of June 2023," continued Mr. Proehl. "Being able to initiate the DMT310 Phase 3 acne program will be a significant step for Dermata as I am confident we can build upon the positive results we saw in our DMT310 Phase 2b acne study," concluded Mr. Proehl.
Corporate Highlights
Dermata successfully closed a $5.0 million public offering priced at-the-market under Nasdaq rules. Dermata closed a public offering of 1,618,123 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 1,618,123 shares of common stock and Series B warrants to purchase up to 1,618,123 shares of common stock at a combined offering price of $3.09 per share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants, for aggregate gross proceeds of $5.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
FDA provided a response to the Company's Type C Meeting Package. The Company received a response from FDA on the Company's Type C CMC meeting package indicating Dermata has provided documentation of its CMC procedures and controls sufficient to support the initiation of DMT310 Phase 3 clinical program for the treatment of acne.
Anticipated Upcoming Milestones
DMT310 End of Phase 2 Responses from FDA. Dermata expects to receive FDA feedback to the Company's End of Phase 2 meeting package by the end of June 2023. Feedback from FDA will help guide Dermata's design of its DMT310 Phase 3 program in moderate-to-severe acne patients.
DMT310 Phase 3 Program in Moderate-to-Severe Acne. After receiving responses from FDA on the End of Phase 2 meeting, the Company intends to initiate its DMT310 Phase 3 acne program in 2H 2023. If the Phase 3 program is successful, the Company intends to submit an New Drug Application to FDA seeking regulatory approval of DMT310 for the treatment of moderate-to-severe acne.
DMT410 Partnership Discussions. Dermata continues partnership discussions surrounding its DMT410 program for the topical delivery of botulinum toxin.
First Quarter 2023 Financial Results
As of March 31, 2023, Dermata had $8.8 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equivalents resulted from $4.2 million net proceeds from the March 2023 public offering, offset by $1.6 million in cash used in operations for the first quarter of 2023. Dermata expects its current cash resources are sufficient to fund operations into the first quarter of 2024.
Research and development expenses were $1.2 million for the quarter ended March 31, 2023, compared to $1.6 million for the quarter ended March 31, 2022. The decrease in research and development expenses was due to decreased clinical expenses, offset by increased non-clinical and CMC expenses for the DMT310 program.
General and administrative expenses were $1.1 million for the quarter ended March 31, 2023, compared to $1.2 million for the quarter ended March 31, 2022, resulting from decreases in insurance policy premiums.
About Dermata Therapeutics
Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: expectations with regard to the timing of meetings and/or responses from submissions with regulatory bodies; the uncertainties inherent in clinical trials; expectations with regard to any potential partnership opportunities for any of the Company's product candidates; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; the success, cost, and timing of its product candidates DMT310 and DMT410 development activities and ongoing and planned clinical trials; and whether the results of any ongoing or planned clinical trials of DMT310 or DMT410 will lead to future product development. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA THERAPEUTICS, INC.
Balance Sheets
March 31, 2023 December 31, 2022
In 000's
(unaudited)
Assets
Cash and cash equivalents
$ 8,767 $ 6,241
Prepaid expenses and other current assets
528 703
Total assets
9,295 6,944
Liabilities
Accounts payable
493 496
Accrued liabilities
714 426
Total liabilities
1,207 922
Equity
8,088 6,022
Total liabilities and equity
$ 9,296 $ 6,944
DERMATA THERAPEUTICS, INC.
Statements of Operations
Three Months Ended March 31,
2023 2022
In 000's, except share and per share data
(unaudited) (unaudited)
Operating expenses
Research and development (1)
$ 1,193 $ 1,596
General and administrative (1)
1,085 1,190
Total operating expenses
2,278 2,786
Loss from operations
(2,278 ) (2,786 )
Interest income, net
(38 ) -
Net loss
$ (2,240 ) $ (2,786 )
Net loss per common share, basic and diluted
$ (2.27 ) $ (5.35 )
Weighted average common shares outstanding, basic and diluted
985,848 520,539
(1) Includes the following stock-based compensation expense (in 000's)
Research and development
$ 48 $ 55
General and administrative
$ 83 $ 158
Investors:
Sean Proehl
Senior Director, Legal and Business Development
info@dermatarx.com
SOURCE: Dermata Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/754322/Dermata-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results
© Copyright 2023 ACCESSWIRE. All Rights Reserved.
Take Payment in Cash on Your Options Trade
Sponsored By : Cboe Global Markets, Inc.
Mini-SPX? index options offer the benefits of ETF options, plus cash settlement and potentially better tax treatment. Learn more
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Nasdaq
SECURITIES
Other Dermata Therapeutics, Inc. Securities
DRMAW
DAILY ADVANCERS
OTCQX Best Market Logo
VIBEF
+ 33.33 %
OTCQX Best Market Logo
DSHKP
+ 28.87 %
OTCQX Best Market Logo
SLHGF
+ 26.76 %
OTCQX Best Market Logo
EMMA
+ 22.22 %
OTCQX Best Market Logo
CTSDF
+ 22.06 %
Get the best-in-class trading platforms that keep getting better with thinkorswim®.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Enter your email
SIGN UP
QUOTE
SYMBOL
OTCM
LAST
59.90
CHANGE
-1.10 (-1.80%)
BID
59.00
ASK
62.45
VOLUME
457
TIME
10:34
Contact
Careers
Market Hours
Glossary
© 2023 OTC Markets Group Inc.Terms of ServiceLinking TermsTrademarksPrivacy StatementRisk WarningSupported BrowsersDo Not Sell My Personal Information
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies-
- Dermata also submitted an end of phase 2 meeting package to the FDA -
SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has received a response from the U.S. Food and Drug Administration ("FDA") to the Company's Type C Chemistry, Manufacturing, and Controls ("CMC") meeting request. The FDA's response stated that the Company has provided documentation of its CMC procedures and controls sufficient to support the initiation of Phase 3 studies. The Company has also submitted an end of phase 2 meeting package to the FDA to discuss clinical requirements to advance DMT310 into Phase 3 development as a treatment for moderate-to-severe acne. The Company expects to receive written feedback on the end of phase 2 meeting package from the FDA by the end of June 2023. Upon agreement with the FDA, the Company plans to initiate the Phase 3 program for acne in the second half of 2023. If the Company is able to successfully complete the Phase 3 program, it believes the results could support submission of a new drug application for DMT310 for the treatment of moderate-to-severe acne.
About Dermata Therapeutics
Dermata Therapeutics is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. In addition to acne, DMT310 has been studied for the treatment of psoriasis and rosacea. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic and medical skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Thanks on DRMA 3.75 exit. There is no board but YS is being loading slowly , take a look. I've grabbed a few for a starter. @1.75
Scary part is within a week the daily volume will barely be 1m
Algo machines at its finest
Where are these shares coming from?
As of February 17, 2023, the number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, was 12,321,848.
Buy ther, same jump like drma
Ther stock..good news about cancer
https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
Massive buying attack!
huge run....
watching for $3 support test
Sorry I have to leave but YS is having a party , Looks like nothing exciting over there. weak news
https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=0&mn=6&dy=0&id=p38090673899
https://www.barchart.com/stocks/quotes/drma/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/drma/opinion
Sell into the big open gap!
The algorithm is not in full affect until the market opens @9:30 right now it's money time with no halts...
Happy Trading
I thought MOCM was going to shut our party down .
Well, it's blowing up now. $3.50 POW!
You have to understand the psychology of the market. WHAT TRADERS WANT
The answer is very basic.
To think they flushed out probably 2m shares in the 1.5-1.65 range to end yesterdays day
What a market this is
Only 7 million volume of PM trading, the other 2.6 mil was from 5-7am ...micro float$$$
DRMA 3.20'S CONGRAT$
MORE2COME?
I watched level 2 all day yesterday
Still scratching my head
Finviz says 600k float 5% short
I don’t get it
2 choices goes back to $1.50s support or we start blowing up to $3.80s which is next major resistance zone
https://finviz.com/quote.ashx?t=DRMA&ty=c&ta=1&p=d
70% PM micro float
I see what you mean. Closed AH $2.42
What a funky movement to finish the day and now they’re ripping it AH
"Hardy Har Har."
DRMA.......................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783
Would love to know these things in advance lol
DRMA: No, Boss --- but her 'Boiler Room' is up by 17+% in the Pre. Mkt. right now!
Are you in DRMA?
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
254
|
Created
|
08/30/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |